Top

International Urogynecology Journal

Published in:

01-11-2019 | Cystitis | Review Article

Biomarkers in the diagnosis and symptom assessment of patients with bladder pain syndrome: a systematic review

Authors: Thais F. Magalhaes, Edmund C. Baracat, Stergios K. Doumouchtsis, Jorge M. Haddad

Published in: International Urogynecology Journal | Issue 11/2019

Abstract

Introduction and hypothesis

Bladder pain syndrome (BPS) is a disease of unknown etiology defined as an unpleasant sensation related to the bladder, associated with lower urinary tract symptoms of more than 6 weeks’ duration, in the absence of any identifiable causes. Despite its impact on quality of life (QoL) and socioeconomic burden, there are no objective methods for the diagnosis or assessment of therapeutic response. We systematically reviewed biomarkers associated with BPS to update the current knowledge on this issue.

Methods

A systematic review of the Cochrane Library, Embase, PubMed/MEDLINE, LILACS, SCOPUS, and ClinicalTrials.gov databases was conducted following the PRISMA statement. Original articles investigating biomarkers for the diagnosis or symptom assessment of patients with BPS were assessed; no language restrictions were applied. Animal or post-mortem studies were excluded.

Results

Of the 478 records retrieved, 11 articles were included. MIF, NGF, Etio-S, APF, and a combined methylhistamine/Il-6 model were increased in BPS urine samples versus controls. Also increased were glyceraldehyde in stool, in addition to the expression of some genes (ARID1A, ARF, CHAT, eNOS, GLI-1, iNOS, MCP-1, NGF, WNT-8A, WNT-10A), nerve density, IL-16, VCAM-1, and ICAM-1 in bladder tissue specimens. In contrast, some fecal bacteria, expression of other genes (CHT, HB-EGF, OCT-1, SMRT-1, WNT11) in the bladder urothelium, and urinary DNA methylation in CpG-sites, MCP-3, G5P1, and HB-EGF were decreased in BPS. As none of the biomarkers was studied more than once, a Forest plot could not be constructed. Only 4 articles reported the relation of biomarkers to symptom scores.

Conclusions

Potential biomarkers for BPS in urine, stool, and bladder biopsy specimens are described. Further research is needed before their use in clinical practice.

Available only for authorised users

Hanno PM, Erickson D, Moldwin R, Faraday MM. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–53. https://doi.org/10.1016/j.juro.2015.01.086.CrossRefPubMed

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology. 2003;61(1):37–49.CrossRefPubMed

Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185(6):2162–70. https://doi.org/10.1016/j.juro.2011.03.064.CrossRefPubMed

Hanno PM, Landis JR, Matthews-Cook Y, Kusek J, Nyberg L Jr. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health interstitial cystitis database study. J Urol. 1999;161(2):553–7.CrossRefPubMed

Denson MA, Griebling TL, Cohen MB, Kreder KJ. Comparison of cystoscopic and histological findings in patients with suspected interstitial cystitis. J Urol. 2000;164(6):1908–11.CrossRefPubMed

Van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7. https://doi.org/10.1016/j.eururo.2007.09.019.CrossRefPubMed

Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186(2):540–4. https://doi.org/10.1016/j.juro.2011.03.132.CrossRefPubMedPubMedCentral

Suskind AM, Berry SH, Ewing BA, Elliott MN, Suttorp MJ, Clemens JQ. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND interstitial cystitis epidemiology male study. J Urol. 2013;189(1):141–5. https://doi.org/10.1016/j.juro.2012.08.088.CrossRefPubMed

Tripp DA, Nickel JC, Fitzgerald MP, Mayer R, Stechyson N, Hsieh A. Sexual functioning, catastrophizing, depression, and pain, as predictors of quality of life in women with interstitial cystitis/painful bladder syndrome. Urology. 2009;73(5):987–92. https://doi.org/10.1016/j.urology.2008.11.049.CrossRefPubMed

10.

Nickel JC, Payne CK, Forrest J, Parsons CL, Wan GJ, Xiao X. The relationship among symptoms, sleep disturbances and quality of life in patients with interstitial cystitis. J Urol. 2009;181(6):2555–61. https://doi.org/10.1016/j.juro.2009.02.030.CrossRefPubMed

11.

Chrysanthopoulou EL, Doumouchtsis SK. Challenges and current evidence on the management of bladder pain syndrome. Neurourol Urodyn. 2014;33(8):1193–201. https://doi.org/10.1002/nau.22475.CrossRefPubMed

12.

Tung A, Hepp Z, Bansal A, Devine EB. Characterizing health care utilization, direct costs, and comorbidities associated with interstitial cystitis: a retrospective claims analysis. J Manag Care Spec Pharm. 2017;23(4):474–82. https://doi.org/10.18553/jmcp.2017.23.4.474.CrossRefPubMed

13.

Keay S, Reeder JE, Koch K, Zhang CO, Grkovic D, Peters K, et al. Prospective evaluation of candidate urine and cell markers in patients with interstitial cystitis enrolled in a randomized clinical trial of Bacillus Calmette Guerin (BCG). World J Urol. 2007;25(5):499–504. https://doi.org/10.1007/s00345-007-0205-4.CrossRefPubMed

14.

Malykhina AP. Neural mechanisms of pelvic organ cross-sensitization. Neuroscience. 2007;149(3):660–72. https://doi.org/10.1016/j.neuroscience.2007.07.053.CrossRefPubMed

15.

Davis NF, Brady CM, Creagh T. Interstitial cystitis/painful bladder syndrome: epidemiology, pathophysiology and evidence-based treatment options. Eur J Obstet Gynecol Reprod Biol. 2014;175:30–7. https://doi.org/10.1016/j.ejogrb.2013.12.041.CrossRefPubMed

16.

Patnaik SS, Lagana AS, Vitale SG, Buttice S, Noventa M, Gizzo S, et al. Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome. Arch Gynecol Obstet. 2017;295(6):1341–59. https://doi.org/10.1007/s00404-017-4364-2.CrossRefPubMed

17.

Siddiqui NY, Helfand BT, Andreev VP, Kowalski JT, Bradley MS, Lai HH, et al. Biomarkers implicated in lower urinary tract symptoms: systematic review and pathway analyses. J Urol. 2019. https://doi.org/10.1097/ju.0000000000000257.CrossRefPubMedPubMedCentral

18.

Grigorescu B, Powers K, Lazarou G. Update on urinary tract markers in interstitial cystitis/bladder pain syndrome. Female Pelvic Med Reconstr Surg. 2016;22(1):16–23. https://doi.org/10.1097/spv.0000000000000224.CrossRefPubMed

19.

Peyronnet B, Bendavid C, Manunta A, Damphousse M, Cheensse C, Brochard C, et al. The role of urinary markers in the assessment and follow-up of lower urinary tract disorders: a literature review. Prog Urol. 2015;25(4):188–99. https://doi.org/10.1016/j.purol.2014.11.004.CrossRefPubMed

20.

Kuo HC. Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis. Int J Urol. 2014;21(Suppl 1):34–41. https://doi.org/10.1111/iju.12311.CrossRefPubMed

21.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. https://doi.org/10.1136/bmj.b2535.CrossRefPubMedPubMedCentral

22.

Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20. https://doi.org/10.1002/nau.20798.CrossRefPubMed

23.

Lamale LM, Lutgendorf SK, Zimmerman MB, Kreder KJ. Interleukin-6, histamine, and methylhistamine as diagnostic markers for interstitial cystitis. Urology. 2006;68(4):702–6. https://doi.org/10.1016/j.urology.2006.04.033.CrossRefPubMed

24.

Braundmeier-Fleming A, Russell NT, Yang W, Nas MY, Yaggie RE, Berry M, et al. Stool-based biomarkers of interstitial cystitis/bladder pain syndrome. Sci Rep. 2016;6:26083. https://doi.org/10.1038/srep26083.CrossRefPubMedPubMedCentral

25.

Parker KS, Crowley JR, Stephens-Shields AJ, van Bokhoven A, Lucia MS, Lai HH, et al. Urinary metabolomics identifies a molecular correlate of interstitial cystitis/bladder pain syndrome in a multidisciplinary approach to the study of chronic pelvic pain (MAPP) research network cohort. EBioMedicine. 2016;7:167–74. https://doi.org/10.1016/j.ebiom.2016.03.040.CrossRefPubMedPubMedCentral

26.

Bradley MS, Burke EE, Grenier C, Amundsen CL, Murphy SK, Siddiqui NY. A genome-scale DNA methylation study in women with interstitial cystitis/bladder pain syndrome. Neurourol Urodyn. 2018;37(4):1485–93. https://doi.org/10.1002/nau.23489.CrossRefPubMedPubMedCentral

27.

Shahid M, Gull N, Yeon A, Cho E, Bae J, Yoon HS, et al. Alpha-oxoglutarate inhibits the proliferation of immortalized normal bladder epithelial cells via an epigenetic switch involving ARID1A. Sci Rep. 2018;8(1):4505. https://doi.org/10.1038/s41598-018-22771-2.CrossRefPubMedPubMedCentral

28.

Vera PL, Preston DM, Moldwin RM, Erickson DR, Mowlazadeh B, Ma F, et al. Elevated urine levels of macrophage migration inhibitory factor in inflammatory bladder conditions: a potential biomarker for a subgroup of interstitial cystitis/bladder pain syndrome patients. Urology. 2018;116:55–62. https://doi.org/10.1016/j.urology.2018.02.039.CrossRefPubMed

29.

Keay S, Zhang CO, Chai T, Warren J, Koch K, Grkovic D, et al. Antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor in men with interstitial cystitis versus chronic pelvic pain syndrome. Urology. 2004;63(1):22–6.CrossRefPubMed

30.

Byrne DS, Sedor JF, Estojak J, Fitzpatrick KJ, Chiura AN, Mulholland SG. The urinary glycoprotein GP51 as a clinical marker for interstitial cystitis. J Urol. 1999;161(6):1786–90.CrossRefPubMed

31.

Corcoran AT, Yoshimura N, Tyagi V, Jacobs B, Leng W, Tyagi P. Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens. World J Urol. 2013;31(1):241–6. https://doi.org/10.1007/s00345-012-0852-y.CrossRefPubMed

32.

Tonyali S, Ates D, Akbiyik F, Kankaya D, Baydar D, Ergen A. Urine nerve growth factor (NGF) level, bladder nerve staining and symptom/problem scores in patients with interstitial cystitis. Adv Clin Exp Med. 2018;27(2):159–63. https://doi.org/10.17219/acem/69231.CrossRefPubMed

33.

Choi D, Han JY, Shin JH, Ryu CM, Yu HY, Kim A, et al. Downregulation of WNT11 is associated with bladder tissue fibrosis in patients with interstitial cystitis/bladder pain syndrome without Hunner lesion. Sci Rep. 2018;8(1). https://doi.org/10.1038/s41598-018-28093-7.

34.

Meyer-Siegler KL, Vera PL. Substance P induced release of macrophage migration inhibitory factor from rat bladder epithelium. J Urol. 2004;171(4):1698–703. https://doi.org/10.1097/01.ju.0000115883.49365.1a.CrossRefPubMed

35.

Kouzoukas DE, Meyer-Siegler KL, Ma F, Westlund KN, Hunt DE, Vera PL. Macrophage migration inhibitory factor mediates PAR-induced bladder pain. PLoS One. 2015;10(5):e0127628. https://doi.org/10.1371/journal.pone.0127628.CrossRefPubMedPubMedCentral

36.

Meyer-Siegler KL, Iczkowski KA, Vera PL. Macrophage migration inhibitory factor is increased in the urine of patients with urinary tract infection: macrophage migration inhibitory factor-protein complexes in human urine. J Urol. 2006;175(4):1523–8. https://doi.org/10.1016/s0022-5347(05)00650-6.CrossRefPubMed

37.

Lowe EM, Anand P, Terenghi G, Williams-Chestnut RE, Sinicropi DV, Osborne JL. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol. 1997;79(4):572–7.CrossRefPubMed

38.

Jacobs BL, Smaldone MC, Tyagi V, Philips BJ, Jackman SV, Leng WW, et al. Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. Can J Urol. 2010;17(1):4989–94.PubMed

39.

Tomaszewski JE, Landis JR, Russack V, Williams TM, Wang LP, Hardy C, et al. Biopsy features are associated with primary symptoms in interstitial cystitis: results from the interstitial cystitis database study. Urology. 2001;57(6 Suppl 1):67–81.CrossRefPubMed

40.

Kim J, Keay SK, Dimitrakov JD, Freeman MR. p53 mediates interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human urothelial cells. FEBS Lett. 2007;581(20):3795–9. https://doi.org/10.1016/j.febslet.2007.06.058.CrossRefPubMedPubMedCentral

41.

Choi BH, You S, Park CS, Cho EH, Park TD, Kim S, et al. Differential perturbation of the interstitial cystitis-associated genes of bladder and urethra in rat model. Cell Cycle. 2017;16(8):749–58. https://doi.org/10.1080/15384101.2017.1295184.CrossRefPubMedPubMedCentral

42.

Li P, Bracamontes J, Katona BW, Covey DF, Steinbach JH, Akk G. Natural and enantiomeric etiocholanolone interact with distinct sites on the rat alpha1beta2gamma2L GABAA receptor. Mol Pharmacol. 2007;71(6):1582–90. https://doi.org/10.1124/mol.106.033407.CrossRefPubMed

43.

Slaunwhite WR Jr, Sandberg AA. Metabolism of 4-C14-testosterone in human subjects. III. Fate of androsterone and etiocholanolone. J Clin Endocrinol Metab. 1958;18(10):1056–66. https://doi.org/10.1210/jcem-18-10-1056.CrossRefPubMed

44.

Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009;15(8):1183–9. https://doi.org/10.1002/ibd.20903.CrossRefPubMed

45.

Shorter B, Lesser M, Moldwin RM, Kushner L. Effect of comestibles on symptoms of interstitial cystitis. J Urol. 2007;178(1):145–52. https://doi.org/10.1016/j.juro.2007.03.020.CrossRefPubMed

46.

Forrest JB, Vo Q. Observations on the presentation, diagnosis, and treatment of interstitial cystitis in men. Urology. 2001;57(6 Suppl 1):26–9.CrossRefPubMed

47.

Thorstenson A, Hagberg O, Ljungberg B, Liedberg F, Jancke G, Holmang S, et al. Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of urinary bladder cancer. Scand J Urol. 2016;50(4):292–7. https://doi.org/10.3109/21681805.2016.1158207.CrossRefPubMed

48.

Fuller TW, Jiang X, Bansal U, Lamm V, Shen B, Wang J, et al. Sex difference in the contribution of GABAB receptors to tibial neuromodulation of bladder overactivity in cats. Am J Physiol Regul Integr Comp Physiol. 2017;312(3):R292–r300. https://doi.org/10.1152/ajpregu.00401.2016.CrossRefPubMed

49.

Kim JM, Xu S, Guo X, Hu H, Dong K, Wang T. Urinary bladder hypertrophy characteristic of male ROMK Bartter’s mice does not occur in female mice. Am J Physiol Regul Integr Comp Physiol. 2018;314(3):R334–R341. https://doi.org/10.1152/ajpregu.00315.2017.CrossRefPubMed

Title: Biomarkers in the diagnosis and symptom assessment of patients with bladder pain syndrome: a systematic review
Authors: Thais F. Magalhaes
Edmund C. Baracat
Stergios K. Doumouchtsis
Jorge M. Haddad
Publication date: 01-11-2019
Publisher: Springer International Publishing
Keywords: Cystitis
Cystitis
Pain Syndromes
Biomarkers
Published in: International Urogynecology Journal / Issue 11/2019
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-019-04075-9

At a glance: The STEP trials

Springer Medicine

Biomarkers in the diagnosis and symptom assessment of patients with bladder pain syndrome: a systematic review

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2019

Variation in bony landmarks and predictors of success with sacral neuromodulation

Pelvic floor muscle knowledge and relationship with muscle strength in Brazilian women: a cross-sectional study

Prevalence of metabolic syndrome and its components in women with and without pelvic organ prolapse and its association with prolapse severity according to the Pelvic Organ Prolapse Quantification system

Histological evidence supports low anesthetic bladder capacity as a marker of a bladder-centric disease subtype in interstitial cystitis/bladder pain syndrome

Robotic sacrocolpopexy: adverse events reported to the FDA over the last decade

Variations in bladder pain syndrome/interstitial cystitis (IC) definitions, pathogenesis, diagnostics and treatment: a systematic review and evaluation of national and international guidelines